Private Advisory Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$14.6M Sell
15,876
-466
-3% -$472K 0.96% 25
2025
Q4
$17.6M Sell
16,342
-4,340
-21% -$4.15M 1.38% 17
2025
Q3
$15.8M Buy
20,682
+2,782
+16% +$2.07M 1.3% 18
2025
Q2
$14M Sell
17,900
-17,382
-49% -$13.5M 1.26% 20
2025
Q1
$29.1M Buy
35,282
+2,886
+9% +$2.4M 3.26% 5
2024
Q4
$25M Buy
32,396
+11,809
+57% +$9.78M 2.8% 7
2024
Q3
$18.2M Buy
20,587
+233
+1% +$209K 2.18% 11
2024
Q2
$18.4M Buy
20,354
+1,103
+6% +$882K 2.4% 10
2024
Q1
$15M Buy
19,251
+1,557
+9% +$1.11M 2.14% 10
2023
Q4
$10.3M Buy
17,694
+906
+5% +$529K 1.79% 13
2023
Q3
$9.02M Buy
16,788
+988
+6% +$509K 1.78% 12
2023
Q2
$7.41M Buy
15,800
+14,469
+1,087% +$6.07M 1.47% 16
2023
Q1
$457K Sell
1,331
-5,337
-80% -$1.8M 0.1% 130
2022
Q4
$2.44M Buy
6,668
+857
+15% +$304K 0.53% 49
2022
Q3
$1.88M Buy
5,811
+364
+7% +$115K 0.43% 59
2022
Q2
$1.77M Buy
5,447
+4,173
+328% +$1.25M 0.4% 58
2022
Q1
$365K Buy
+1,274
New +$328K 0.07% 122

Other funds holding LLY

Private Advisory Group's LLY Position: Q1 2026 in Review

Private Advisory Group reduced its Eli Lilly (LLY) stake by 2.9% in Q1 2026, selling an estimated $472K and leaving 15,876 shares worth $14.6M. The position accounts for 0.96% of the portfolio, ranked #25.

Private Advisory Group first reported a position in LLY in Q1 2022 and has held it in 17 quarters since. The position peaked at $29.1M in Q1 2025. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Private Advisory Group held 15,876 shares of Eli Lilly worth $14.6M as of Q1 2026.
  • Private Advisory Group sold 466 Eli Lilly shares in Q1 2026, an estimated $472K.
  • Eli Lilly made up 0.96% of Private Advisory Group's portfolio in Q1 2026, its #25 holding.
  • Private Advisory Group first reported a position in Eli Lilly in Q1 2022 and has held it in 17 quarters since.
  • Private Advisory Group's Eli Lilly position peaked at $29.1M in Q1 2025.
  • 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Private Advisory Group's 13F filing for Q1 2026, filed 8 May 2026.